Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | NTRK2 A203T |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
NTRK2 A203T | hematologic cancer | sensitive | Entrectinib | Preclinical - Cell culture | Actionable | In a preclinical study, Rozlytrek (entrectinib) decreased Ntrk2 phosphorylation and viability and increased apoptosis in a transformed cell line expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 | |
NTRK2 A203T | hematologic cancer | sensitive | Foretinib | Preclinical - Cell culture | Actionable | In a preclinical study, Foretinib (GSK1363089) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 | |
NTRK2 A203T | hematologic cancer | sensitive | Cabozantinib | Preclinical - Cell culture | Actionable | In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 | |
NTRK2 A203T | hematologic cancer | sensitive | Crizotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xalkori (crizotinib) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 | |
NTRK2 A203T | hematologic cancer | sensitive | Crenolanib | Preclinical - Cell culture | Actionable | In a preclinical study, Crenolanib (CP-868596) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 | |
NTRK2 A203T | hematologic cancer | sensitive | Ponatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Iclusig (ponatinib) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 | |
NTRK2 A203T | hematologic cancer | sensitive | Larotrectinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vitrakvi (larotrectinib) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 |